Table 1.

Association between PCDHGA9 and clinicopathological features in gastric cancer (n = 83)

	N	PCDHGA9 expression			P-value
		Negative (41)	Weak positive (29)	Strong positive (13)
Age (years)					0.985
<65	39	19 (48.7)	14 (35.9)	6 (15.4)
≥65	44	22 (50.0)	15 (34.1)	7 (15.9)
Gender					0.587
Male	55	28 (50.9)	20 (36.4)	7 (12.7)
Female	28	13 (46.4)	9 (32.1)	6 (21.4)
Tumor location					0.351
Gastric fundus	9	3 (33.3)	3 (33.3)	3 (33.3)
Gastric corpus	73	38 (52.1)	25 (34.3)	10 (13.7)
Pylorus	1	0 (0)	1 (100.0)	0 (0)
Tumor sizes (cm)					0.556
<3	10	4 (40.0)	5 (50.0)	1 (10.0)
≥3	73	37 (50.7)	24 (32.9)	12 (16.4)
T stage					<0.001
T1	8	0 (0)	2 (25.0)	6 (75.0)
T2	8	3 (37.5)	0 (0)	5 (62.5)
T3	53	28 (52.8)	23 (43.4)	2 (3.8)
T4	14	10 (71.4)	4 (28.6)	0 (0)
N stage					0.003
N0	19	3 (15.8)	11 (57.9)	5 (26.3)
N1	14	5 (35.7)	5 (35.7)	4 (28.6)
N2	24	16 (66.7)	4 (16.7)	4 (16.7)
N3	26	17 (65.4)	9 (34.6)	0 (0)
M stage					0.006
M0	74	32 (43.2)	29 (39.2)	13 (17.6)
M1	9	9 (100.0)	0 (0)	0 (0)
UICC stage					<0.001
I	8	0 (0)	1 (12.5)	7 (87.5)
II	22	4 (18.2)	13 (59.1)	5 (22.7)
III	43	28 (65.1)	14 (32.6)	1 (2.3)
IV	10	9 (90.0)	1 (10.0)	0 (0)
Vessel invasion					0.290
No	70	32 (45.7)	26 (37.1)	12 (17.1)
Yes	13	9 (69.2)	3 (23.1)	1 (7.7)
Nerve invasion					0.461
No	80	40 (50.0)	27 (33.8)	13 (1.25)
Yes	3	1 (33.3)	2 (66.7)	0 (0)
Differentiation					0.001
High	1	0 (0)	0 (0)	1 (100)
Moderate	36	13 (36.1)	16 (44.4)	7 (19.4)
Low	46	28 (60.9)	13 (28.3)	5 (10.9)
Relapse					0.001
No	44	15 (34.1)	17 (38.6)	12 (27.3)
Yes	39	26 (66.7)	12 (30.8)	1 (2.6)